| 吴英英,程 聪,赖文娟,邱志刚,张 丽.替诺福韦联合聚乙二醇干扰素α-2b注射液对慢性乙型肝炎患者HBe Ag血清学转换率和阴转率的影响[J].,2021,(10):1938-1941 |
| 替诺福韦联合聚乙二醇干扰素α-2b注射液对慢性乙型肝炎患者HBe Ag血清学转换率和阴转率的影响 |
| The Effect of Tenofovir Combined with Peginterferon α-2b Injection on HBe Ag Seroconversion Rate and Negative Conversion Rate in Patients with Chronic Hepatitis B |
| 投稿时间：2020-12-02 修订日期：2020-12-24 |
| DOI：10.13241/j.cnki.pmb.2021.10.029 |
| 中文关键词: 替诺福韦 聚乙二醇干扰素α-2b 慢性乙型肝炎 血清学转换率 阴转率 |
| 英文关键词: Tenofovir Peginterferon alpha-2b Chronic hepatitis B Seroconversion rate Negative conversion rate |
| 基金项目:福建省自然科学基金项目（2018J0547） |
|
| 摘要点击次数: 583 |
| 全文下载次数: 365 |
| 中文摘要: |
| 摘要 目的：探讨替诺福韦联合聚乙二醇干扰素α-2b注射液对慢性乙型肝炎患者HBe Ag血清学转换率和阴转率的影响。方法：2018年2月到2020年8月选择在我院联合汀州医院诊治的慢性乙型肝炎患者104例，根据随机数字表法把患者分为联合组与对照组各52例。对照组给予聚乙二醇干扰素α-2b注射液治疗，联合组给予替诺福韦联合聚乙二醇干扰素α-2b注射液治疗，两组都治疗观察48 w。对比两组治疗前后患者的HBeAg血清学转换情况及HBV-DNA的转阴情况，血清谷丙转氨酶(Alanine transaminase，ALT)、谷草转氨酶(Aspartate transaminase，AST)含量。结果：治疗后联合组的HBe Ag血清学转换率为11.54 %，高于对照组的3.85 %(P>0.05)。治疗后联合组的HBV DNA 转阴率为100 %，高于对照组的71.17 %(P<0.05)。两组治疗后的血清ALT与AST值低于治疗前(P<0.05)，联合组低于对照组(P<0.05)。结论：替诺福韦联合聚乙二醇干扰素α-2b注射液对慢性乙型肝炎患者能提高HBe Ag血清学转换率和阴转率，改善患者的肝功能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of tenofovir combined with peginterferon α-2b injection on HBe Ag seroconversion rate and negative conversion rate in patients with chronic hepatitis B. Methods: From February 2018 to August 2020, 104 cases patients with chronic hepatitis B who were diagnosed and treated in our hospital and Tingzhou hospital were selected as the research objects. All the cases were divided into combination group and a control group with 52 cases each groups accorded to the random number table method. The control group were treated with peginterferon α-2b injection, and the combination group were treated with tenofovir combined with peginterferon α-2b injection. Two groups were treated for 48 weeks. Compare the HBeAg seroconversion and HBV DNA conversion of the patients before and after the correct treatment, and the serum alanine aminotransferase (alanine aminotransferase, ALT) and aspartate aminotransferase (aspartate aminotransferase, AST) levels of the patients. Results: After treatment, the HBe Ag seroconversion rate of the combined group was 11.54 %, which was higher than that of the control group of 3.85 %, but the comparison was not statistically significant(P>0.05). After treatment, the negative rate of HBV DNA in the combined group was 100 %, which was higher than 71.17 % in the control group(P<0.05). The serum ALT and AST values of the two groups after treatment were lower than before treatment (P<0.05), and the combination group were lower than the control group (P<0.05). Conclusion: Tenofovir combined with peginterferon α-2b injection can increase the seroconversion rate and negative conversion rate of HBe Ag in patients with chronic hepatitis B, and improve the liver function of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
